Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Pembrolizumab +1 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
San Marcos, California
This trial is testing a new combination of drugs to treat stage IV NSCLC that has spread to the bone. The drugs are Radium-223 dichloride, which is a radioactive agent that kills cancer cells, and pembrolizumab, which is an immunologic checkpoint blocker. The researchers want to measure tumor shrinkage in response to treatment and how long that shrinkage lasts.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.